Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
1.14.2011

On Whistleblowers

By Ken Wexler, Founder and Managing Partner
Columns, In The News, Ken Wexler

On January 1, the venerable show 60 Minutes ran a story about mega-pharmaceutical maker GlaxoSmithKline (“GSK”) pleading guilty to distributing adulterated drugs, a felony.

The company paid $750 million to settle the criminal conviction and a whistleblower suit that exposed Glaxo’s sale out of a plant in Puerto Rico contaminated Paxil CR, Avandamet (a diabetes drug), Kytril (a drug given to cancer patients) and Bactroban, all manufactured without the most basic of quality controls.

According to the whistleblower, when she inspected the plant and saw what was happening, she contacted the vice president of quality for North America and told him that “he needed to shut down the factory and call the FDA.”   She “… urged him to stop the trucks that were leaving the dock that day.”

GSK, however, did not shut down the factory, did not call the FDA and did not stop the trucks from taking out the drugs and putting them into the stream of commerce.  Finally, after eight months of going through channels and warning GSK of what was happening, the whistleblower quit and, thank goodness, blew the whistle on the company’s criminally dangerous behavior.

This is obviously a disturbing story.  We all buy medications from time-to-time and, when we take them, we expect them to be pristine in quality, free from bacteria and other contamination, in the prescribed dosages and otherwise what they are supposed to be.  It would just never occur to me that it would be any other way.

Yet there is something more to this story than the outrageous behavior of GSK that is detailed.   The recent Dodd-Frank financial reform legislation created a new whistleblower program through the Securities and Exchange Commission.  The idea is to incentivize employees to report government financial fraud, to hopefully deter such conduct and prevent the type of financial abuse that continues to be exposed by the ongoing economic meltdown.

Who could possibly be opposed to ensuring that our financial markets are run honestly?  It seems to me like a no-brainer.  Yet, critics of the program have argued that employees should not be “encouraged” to bypass internal corporate procedures.  These “critics” are, of course, the very corporations whose frauds are targeted for exposure by the legislation.  Apparently, they would rather handle these issues themselves, internally and without the “threat” of government intervention and public accountability.

Well, GSK had so-called “internal controls.”  The person who warned of abuses in the Puerto Rico manufacturing plant used those controls, reported through channels and what good did that do? None. Zero. Zip. Nothing.  The only avenue that stopped the problem was the federal False Claims Act, a whistleblower statute that exists independently of the Dodd-Frank financial reforms.

So I have no sympathy for the Dodd-Frank whistleblower critics.  If they do not want to be bothered by the provisions, they should simply act honestly in the first place.

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
    • Ed Wallace
  • Practice Areas
    • Consumer Protection
    • Mass Tort Litigation
    • Business & Commercial Litigation
    • Healthcare Litigation
    • Employment Litigation
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • Featured Investigations
  • The Firm
    • News releases
    • Around The World
    • Our Professionals
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Featured Cases
  • awards
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP